BioNTechRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
BioNTech (BNTX) reported revenue of $114.00M in Q2 2026.
Q1 2018-Q2 2026(All available data)
Q1 2018-Q2 2026(All available data)
BioNTechmRNA company and Pfizer partner on Comirnaty. Held more than 50% global COVID share in fall 2025. Closed CureVac in December 2025. 2026 equity story is oncology; vaccines are the cash residual.
BioNTech (BNTX) is a Biotechnology company. mRNA company and Pfizer partner on Comirnaty. Held more than 50% global COVID share in fall 2025. Closed CureVac in December 2025. 2026 equity story is oncology; vaccines are the cash residual. It was founded in 2008, is headquartered in Mainz, Germany and employs about 6,772 people.
Track BioNTech's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 19, 2026.
Sterling groups BioNTech in the Vaccines sector, alongside GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and AstraZeneca (AZN).
If you are researching BioNTech, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines sector on Sterling.